[Clinical presentation, diagnosis, prognosis, and risk-adapted treatment of chronic BCR::ABL1-negative myeloproliferative neoplasms].
文献摘要
Myeloproliferative neoplasms are characterized by the neoplastic transformation of hematopoietic stem cells and the associated hyperproliferation of myeloid cell lineages, such as granulopoiesis, erythropoiesis, or megakaryopoiesis. These diseases follow a chronic, protracted course and can develop during the aging process against a background of clonal hematopoiesis. The peak incidence of myeloproliferative neoplasms occurs between the ages of 65 and 75. Myeloproliferative neoplasms are among the most common reasons for oncology consultations, and given demographic trends in Europe, a further increase in newly diagnosed cases is expected in the coming decades. The following overview focuses on the three classic BCR::ABL1-negative myeloproliferative neoplasms-polycythemia vera, essential thromcythemia, and primary myelofibrosis-and addresses their epidemiology, clinical characteristics, diagnosis, prognosis, and treatment options.